(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 64.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Ars Pharmaceuticals's revenue in 2026 is $98,986,000.On average, 7 Wall Street analysts forecast SPRY's revenue for 2026 to be $14,357,265,620, with the lowest SPRY revenue forecast at $12,872,681,853, and the highest SPRY revenue forecast at $16,468,452,970. On average, 7 Wall Street analysts forecast SPRY's revenue for 2027 to be $27,012,473,329, with the lowest SPRY revenue forecast at $22,188,320,861, and the highest SPRY revenue forecast at $32,486,069,131.
In 2028, SPRY is forecast to generate $44,547,443,333 in revenue, with the lowest revenue forecast at $31,336,137,357 and the highest revenue forecast at $52,452,976,021.